Britain and America have finalized a key bilateral deal that will keep no import taxes on UK drug products going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost spending on medicines through the public health system. This move secures that tariffs on these vital goods will stay at nothing for a period of 36 months.
This agreement follows recent statements to significantly raise duties on branded drug products, with potential rates discussed as high as one hundred percent.
"This arrangement between the United Kingdom bolsters the global environment for innovative medicines and brings much-needed balance to U.S.–U.K. drug exports," a release said.
Commercial Impact
Pharmaceuticals are one of the Britain's most significant exports to the United States, which is clearly the primary destination for major British pharmaceutical firms.
Statistics show that in the 12 months leading up to the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that period.
"This guarantee secures jobs, increases capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed UK Commitments
The deal entails several key changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to increase overall public funding on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be limited at 15%. Previously, repayments were more than 20%.
Industry Background
This agreement comes amid a ongoing dispute between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were heightened by claims that American patients were paying a premium for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or abandoned, while major investments have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.